MyAverix Finance
SHG · Healthcare
Vcanbio Cell & Gene Engineering Corp Ltd (600645)
Biotechnology
Vcanbio Cell & Gene Engineering Corp Ltd (600645) is listed on SHG in the Healthcare sector. Industry: Biotechnology. As of 2026-03-28, reported market cap is $14.92B, P/E ratio is 187.53, net margin is 5.1%. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.
Key metrics for 600645
Vcanbio Cell & Gene Engineering Corp Ltd (600645) — FAQ
What is Vcanbio Cell & Gene Engineering Corp Ltd's market cap?
Vcanbio Cell & Gene Engineering Corp Ltd (600645) has a reported market cap of $14.92B (data as of 2026-03-28).
What is 600645's P/E ratio?
The price-to-earnings (P/E) ratio for Vcanbio Cell & Gene Engineering Corp Ltd (600645) is 187.53 (data as of 2026-03-28).
Does Vcanbio Cell & Gene Engineering Corp Ltd pay a dividend?
Dividend yield is not available in the current snapshot for Vcanbio Cell & Gene Engineering Corp Ltd (600645). Check the MyAverix Finance app for the latest dividend data.
What sector is Vcanbio Cell & Gene Engineering Corp Ltd in?
Vcanbio Cell & Gene Engineering Corp Ltd (600645) is classified in the Healthcare sector (Biotechnology industry).
What exchange is 600645 listed on?
600645 is listed on SHG.
What is Vcanbio Cell & Gene Engineering Corp Ltd's net margin?
Vcanbio Cell & Gene Engineering Corp Ltd (600645) reports a net margin of 5.1% (data as of 2026-03-28).
Full report in the app
Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.